A groundbreaking UK study led by Southampton researchers will evaluate the clinical validity of the Avantect® Pancreatic Cancer Test in detecting early-stage pancreatic cancer in up to 15,000 newly diagnosed type 2 diabetes patients.
This large-scale trial, in collaboration with ClearNote Health, aims to improve early detection and patient outcomes for one of the deadliest cancers.
Read more about the study and its potential impact: